Singapore markets open in 2 hours 59 minutes

Novo Nordisk A/S (NONOF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
109.00+5.45 (+5.26%)
At close: 03:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close103.55
Bid0.00 x 0
Ask0.00 x 0
Day's range104.13 - 109.00
52-week range76.75 - 123.70
Avg. volume13,910
Market cap249.445B
Beta (5Y monthly)0.32
PE ratio (TTM)36.26
EPS (TTM)3.01
Earnings dateN/A
Forward dividend & yield1.57 (1.52%)
Ex-dividend date25 Mar 2022
1y target estN/A
  • Zacks

    Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod

    Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.

  • Motley Fool

    3 Unstoppable Stocks to Buy in May

    Prosper Junior Bakiny (Novo Nordisk): For the past several decades, Novo Nordisk has been a leader in the market for diabetes drugs. As of February 2022, the company held a 30.5% share of the diabetes care market, an increase from the 29.3% slice of the pie it had in February 2021. Novo Nordisk's dominance in this therapeutic area is one reason it has outperformed the broader market in each of the past one, five, 10, and 20 years.

  • Zacks

    Prothena (PRTA) Q1 Earnings Beat, Pipeline Progress in Focus

    Prothena beats on earnings and revenues in the first quarter of 2022. The company's progress with its AD pipeline is encouraging.